Mining/VBG
the/DT
Proteome/NN
of/IN
Fusobacterium/NN
nucleatum/NN
subsp/NN
./.
====================
nucleatum/NN
ATCC/NN
25586/CD
for/IN
Potential/JJ
Therapeutics/NNS
Discovery/NN
:/:
An/DT
In/IN
Silico/NN
Approach/NN
./.
====================
The/DT
plethora/NN
of/IN
genome/NN
sequence/NN
information/NN
of/IN
bacteria/NNS
in/IN
recent/JJ
times/NNS
has/VBZ
ushered/VBN
in/IN
many/JJ
novel/JJ
strategies/NNS
for/IN
antibacterial/JJ
drug/NN
discovery/NN
and/CC
facilitated/VBD
medical/JJ
science/NN
to/TO
take/VB
up/IN
the/DT
challenge/NN
of/IN
the/DT
increasing/VBG
resistance/NN
of/IN
pathogenic/JJ
bacteria/NNS
to/TO
current/JJ
antibiotics/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
adopted/VBD
subtractive/JJ
genomics/NNS
approach/NN
to/TO
analyze/VB
the/DT
whole/JJ
genome/NN
sequence/NN
of/IN
the/DT
Fusobacterium/NN
nucleatum/NN
,/,
a/DT
human/JJ
oral/JJ
pathogen/NN
having/VBG
association/NN
with/IN
colorectal/JJ
cancer/NN
./.
====================
Our/PRP$
study/NN
divulged/VBD
1,499/CD
proteins/NNS
of/IN
F./NN
nucleatum/NN
,/,
which/WDT
have/VBP
no/DT
homolog/NN
's/POS
in/IN
human/JJ
genome/NN
./.
====================
These/DT
proteins/NNS
were/VBD
subjected/VBN
to/TO
screening/VBG
further/RBR
by/IN
using/VBG
the/DT
Database/NN
of/IN
Essential/JJ
Genes/NNS
(/(
DEG/NN
)/)
that/WDT
resulted/VBD
in/IN
the/DT
identification/NN
of/IN
32/CD
vitally/RB
important/JJ
proteins/NNS
for/IN
the/DT
bacterium/NN
./.
====================
Subsequent/JJ
analysis/NN
of/IN
the/DT
identified/VBN
pivotal/JJ
proteins/NNS
,/,
using/VBG
the/DT
Kyoto/JJ
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
Automated/JJ
Annotation/NN
Server/NN
(/(
KAAS/NN
)/)
resulted/VBD
in/IN
sorting/VBG
3/CD
key/JJ
enzymes/NNS
of/IN
F./NNP
nucleatum/NN
that/DT
may/MD
be/VB
good/JJ
candidates/NNS
as/IN
potential/JJ
drug/NN
targets/NNS
,/,
since/IN
they/PRP
are/VBP
unique/JJ
for/IN
the/DT
bacterium/NN
and/CC
absent/JJ
in/IN
humans/NNS
./.
====================
In/IN
addition/NN
,/,
we/PRP
have/VBP
demonstrated/VBN
the/DT
three/CD
dimensional/JJ
structure/NN
of/IN
these/DT
three/CD
proteins/NNS
./.
====================
Finally/RB
,/,
determination/NN
of/IN
ligand/NN
binding/NN
sites/NNS
of/IN
the/DT
2/CD
key/JJ
proteins/NNS
as/IN
well/RB
as/IN
screening/NN
for/IN
functional/JJ
inhibitors/NNS
that/IN
best/JJS
fitted/VBN
with/IN
the/DT
ligands/NNS
sites/NNS
were/VBD
conducted/VBN
to/TO
discover/RB
effective/JJ
novel/JJ
therapeutic/JJ
compounds/NNS
against/IN
F./NNP
nucleatum/NN
./.
====================
Fusobacterium/NN
nucleatum/NN
is/VBZ
a/DT
gram-negative/JJ
anaerobic/JJ
bacterium/NN
which/WDT
plays/VBZ
vital/JJ
role/NN
in/IN
the/DT
architecture/NN
of/IN
oral/JJ
biofilms/NNS
./.
====================
This/DT
dominant/JJ
oral/JJ
bacterium/NN
is/VBZ
very/RB
much/RB
associated/VBN
with/IN
periodontitis/NN
,/,
a/DT
very/RB
common/JJ
infectious/JJ
disease/NN
worldwide/NN
./.
====================
F./NNP
nucleatum/NN
also/RB
affects/VBZ
some/DT
other/JJ
bodily/RB
infections/NNS
such/JJ
as/IN
peritonsillar/JJ
abscesses/NNS
,/,
endocarditis/NN
,/,
skin/NN
ulcers/NNS
,/,
and/CC
septic/JJ
arthritis/NN
[/(
1234/CD
]/)
./.
====================
Coincidentally/RB
,/,
it/PRP
may/MD
cause/VB
severe/JJ
infections/NNS
in/IN
a/DT
child/JJ
's/POS
body/NN
./.
====================
In/IN
many/JJ
studies/NNS
,/,
F./NNP
nucleatum/NN
is/VBZ
appeared/VBD
to/TO
be/VB
related/JJ
with/IN
preterm/JJ
birth/IN
and/CC
has/VBZ
been/VBN
found/VBN
in/IN
the/DT
placenta/NN
,/,
amniotic/JJ
fluid/NN
,/,
and/CC
chorioamnionic/JJ
membranes/NNS
of/IN
women/NNS
delivering/VBG
ahead/RB
of/IN
time/NN
./.
====================
Preterm/JJ
birth/IN
is/VBZ
the/DT
leading/VBG
cause/VBP
of/IN
child/JJ
mortality/NN
and/CC
morbidity/NN
,/,
accounting/VBG
for/IN
7/CD
%/NN
to/TO
11/CD
%/NN
of/IN
all/DT
births/NNS
in/IN
the/DT
United/JJ
States/NNS
alone/RB
[/(
5/CD
]/)
./.
====================
Moreover/RB
,/,
many/JJ
studies/NNS
have/VBP
linked/VBN
F./NNP
nucleatum/NN
with/IN
colorectal/JJ
cancer/NN
;/:
in/IN
addition/NN
,/,
a/DT
mechanism/NN
has/VBZ
been/VBN
reported/VBN
by/IN
which/WDT
F./NNP
nucleatum/NN
promotes/VBZ
colonic/JJ
tumor/NN
formation/NN
without/IN
following/VBG
the/DT
usual/JJ
mechanism/NN
of/IN
instigating/JJ
colonic/JJ
inflammation/NN
or/CC
otherwise/RB
irritating/VBG
the/DT
colon/NN
tissue/NN
and/CC
thereby/RB
demonstrating/VBG
a/DT
direct/JJ
and/CC
specific/JJ
colonic/JJ
carcinogenesis/NN
[/(
67/CD
]/)
./.
====================
Appropriate/NN
antibiotic/JJ
therapy/NN
and/CC
surgical/JJ
drainage/VBP
constitute/VBP
the/DT
basis/NN
for/IN
treating/VBG
fusobacterial/JJ
infections/NNS
./.
====================
However/RB
,/,
the/DT
emergence/NN
of/IN
multidrug/JJ
resistant/JJ
strains/NNS
of/IN
F./NN
nucleatum/NN
has/VBZ
made/VBN
it/PRP
difficult/JJ
to/TO
guide/NN
the/DT
choice/NN
of/IN
empiric/JJ
treatment/NN
./.
====================
The/DT
first/JJ
case/NN
of/IN
resistance/NN
to/TO
penicillin/NN
by/IN
fusobacteria/NN
was/VBD
reported/VBN
in/IN
the/DT
mid-1980s/NNS
./.
====================
There/EX
is/VBZ
evidence/NN
of/IN
an/DT
increased/VBN
frequency/NN
of/IN
Î²-lactamase/NN
production/NN
by/IN
fusobacteria/NN
[/(
8/CD
]/)
./.
====================
The/DT
incidence/NN
of/IN
widespread/JJ
resistance/NN
of/IN
Fusobacterium/NN
spp/NN
./.
====================
to/TO
erythromycin/NN
and/CC
other/JJ
macrolides/NNS
has/VBZ
been/VBN
reported/VBN
as/IN
well/RB
[/(
9/CD
]/)
./.
====================
Though/IN
antibiotics/NNS
like/IN
clindamycin/NN
,/,
chloramphenicol/NN
,/,
carbenicillin/NN
,/,
cefoperazone/NN
,/,
cefamandole/JJ
[/(
10/CD
]/)
,/,
and/CC
amoxicillin/IN
[/(
11/CD
]/)
are/VBP
shown/VBN
to/TO
be/VB
active/JJ
against/IN
this/DT
pathogen/NN
,/,
ever/RB
evolving/VBG
antibacterial/JJ
resistance/NN
[/(
12/CD
]/)
,/,
chances/NNS
of/IN
cross/JJ
resistance/NN
[/(
13/CD
]/)
,/,
and/CC
the/DT
associated/VBN
untoward/IN
effects/NNS
of/IN
antibiotics/NNS
[/(
14/CD
]/)
persistently/RB
urge/JJ
the/DT
researchers/NNS
to/TO
explore/VB
more/RBR
promising/VBG
and/CC
safer/RBR
drug/NN
targets/NNS
./.
====================
More/RBR
importantly/RB
,/,
increasing/VBG
evidence/NN
of/IN
association/NN
between/IN
Fusobacterium/NN
and/CC
colorectal/JJ
cancer/NN
has/VBZ
even/RB
more/RBR
intensified/JJ
this/DT
urge/JJ
./.
====================
In/IN
this/DT
context/NN
,/,
this/DT
study/NN
aimed/VBD
to/TO
explore/VB
some/DT
potential/JJ
novel/JJ
drug/NN
targets/NNS
other/JJ
than/IN
the/DT
aforementioned/VBN
targets/NNS
./.
====================
We/PRP
have/VBP
adopted/VBN
an/DT
approach/NN
focusing/VBG
on/IN
two/CD
important/JJ
criteria/NNS
./.
====================
Firstly/RB
,/,
the/DT
identified/VBN
target/NN
protein/NN
should/MD
be/VB
indispensable/JJ
for/IN
the/DT
survival/NN
of/IN
the/DT
pathogen/NN
./.
====================
Secondly/RB
,/,
the/DT
target/NN
protein/NN
should/MD
not/RB
be/VB
homologous/JJ
to/TO
any/DT
protein/NN
of/IN
the/DT
human/JJ
proteome/NN
./.
====================
The/DT
nonhomolog/NN
property/NN
of/IN
these/DT
target/NN
proteins/NNS
check/VBP
the/DT
chance/NN
of/IN
the/DT
cross-reaction/NN
with/IN
the/DT
human/JJ
host/NN
and/CC
thus/RB
ascertains/VBZ
highly/RB
selective/JJ
therapeutic/JJ
targets/NNS
./.
====================
This/DT
may/MD
facilitate/VB
minimizing/JJ
the/DT
adverse/JJ
reactions/NNS
of/IN
the/DT
prospective/JJ
drug/NN
[/(
15/CD
]/)
./.
====================
In/IN
this/DT
way/NN
,/,
we/PRP
have/VBP
identified/VBN
some/DT
potential/JJ
drug/NN
targets/NNS
which/WDT
are/VBP
not/RB
only/RB
human/JJ
non-homologous/JJ
essential/JJ
proteins/NNS
in/IN
unique/JJ
metabolic/JJ
pathway/NN
of/IN
the/DT
pathogen/NN
but/CC
also/RB
circumvent/JJ
the/DT
resistant/JJ
mechanism/NN
of/IN
current/JJ
targets/NNS
[/(
16/CD
]/)
./.
====================
Moreover/RB
,/,
we/PRP
have/VBP
predicted/VBN
the/DT
three/CD
dimensional/JJ
(/(
3D/NN
)/)
structure/NN
of/IN
these/DT
target/NN
proteins/NNS
and/CC
analyzed/VBD
ligand/NN
binding/NN
sites/NNS
and/CC
corresponding/VBG
ligands/NNS
of/IN
the/DT
best/JJS
proteins/NNS
to/TO
facilitate/VB
the/DT
search/NN
for/IN
novel/JJ
drugs/NNS
which/WDT
might/MD
potentially/RB
arrest/VB
the/DT
growth/NN
of/IN
F./NNP
nucleatum/NN
./.
====================
The/DT
sequential/JJ
diagram/NN
to/TO
identify/VB
and/CC
to/TO
characterize/VB
the/DT
putative/JJ
drug/NN
targets/NNS
of/IN
Fusobacterium/NN
nucleatum/NN
subsp/NN
./.
====================
nucleatum/NN
ATCC/NN
25586/CD
is/VBZ
illustrated/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
Retrieval/NN
of/IN
the/DT
proteome/NN
of/IN
F./NN
nucleatum/NN
====================
The/DT
complete/JJ
proteome/NN
of/IN
F./NN
nucleatum/NN
was/VBD
retrieved/VBN
in/IN
FAST/NN
alignment/NN
(/(
FASTA/NN
)/)
format/VBP
from/IN
National/JJ
Center/NN
for/IN
Biotechnology/NN
Information/NN
(/(
NCBI/NN
;/:
http/RB
:/:
//www.ncbi.nlm.nih.gov//JJ
)/)
./.
====================
CD-HIT/NN
analysis/NN
====================
The/DT
proteins/NNS
were/VBD
subjected/VBN
to/TO
Cluster/NN
Database/NN
at/IN
High/JJ
Identity/NN
with/IN
Tolerance/NN
(/(
CD-HIT/NN
)/)
analysis/NN
(/(
http/NN
:/:
//weizhong-lab.ucsd.edu/cdhit_suite/cgi-bin/index.cgi/NNP
)/)
[/(
17/CD
]/)
./.
====================
The/DT
program/NN
takes/VBZ
a/DT
FASTA/NN
format/IN
sequence/NN
database/NN
as/IN
input/NN
and/CC
produces/VBZ
a/DT
set/NN
of/IN
non-redundant/JJ
,/,
representative/JJ
sequences/NNS
as/IN
output/RB
./.
====================
The/DT
process/NN
was/VBD
carried/VBN
out/RP
with/IN
a/DT
sequence/NN
identity/NN
cutoff/JJ
of/IN
0.6/CD
,/,
thus/RB
eliminating/VBG
redundant/JJ
sequences/NNS
with/IN
more/RBR
than/IN
60/CD
%/NN
identity/NN
[/(
181920/CD
]/)
./.
====================
The/DT
resultant/JJ
proteins/NNS
were/VBD
grouped/VBN
as/IN
Set1/NN
proteome/NN
./.
====================
Elimination/NN
of/IN
human/JJ
homologous/JJ
proteins/NNS
of/IN
F./NN
nucleatum/NN
====================
Protein/NN
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
(/(
BLASTP/NN
)/)
analysis/NN
(/(
http/NN
:/:
//blast.ncbi.nlm.nih.gov/Blast.cgi/NNP
)/)
was/VBD
carried/VBN
out/RP
for/IN
the/DT
Set1/NN
proteome/JJ
against/IN
the/DT
proteome/JJ
of/IN
Homo/NN
sapiens/NNS
./.
====================
Proteins/NNS
with/IN
an/DT
E-value/JJ
(/(
expectation/NN
value/NN
)/)
10â4/CD
were/VBD
eliminated/VBN
;/:
assuming/VBG
that/DT
they/PRP
have/VBP
a/DT
certain/JJ
level/NN
of/IN
homology/NN
with/IN
the/DT
host/NN
genome/NN
[/(
21/CD
]/)
./.
====================
The/DT
resultant/JJ
data/NNS
set/VBP
(/(
Set2/NN
proteome/VBP
)/)
of/IN
F./NN
nucleatum/NN
had/VBD
no/DT
homology/NN
with/IN
the/DT
human/JJ
proteome/NN
./.
====================
Identification/NN
of/IN
non-human/JJ
homologous/JJ
essential/JJ
proteins/NNS
in/IN
F./NN
nucleatum/NN
====================
Then/RB
the/DT
Set2/NN
proteome/JJ
was/VBD
subjected/VBN
to/TO
BLASTP/NN
analysis/NN
with/IN
Database/NN
of/IN
Essential/JJ
Genes/NNS
(/(
DEG/NN
;/:
http/RB
:/:
//tubic.tju.edu.cn/deg//JJ
)/)
,/,
which/WDT
contains/VBZ
all/DT
the/DT
essential/JJ
genes/NNS
currently/RB
available/JJ
./.
====================
An/DT
E-value/JJ
of/IN
10â100/CD
was/VBD
set/NN
as/IN
the/DT
cutoff/JJ
value/NN
[/(
22/CD
]/)
./.
====================
Thus/RB
,/,
a/DT
Set3/NN
proteome/VBP
of/IN
F./NN
nucleatum/NN
was/VBD
obtained/VBN
by/IN
grouping/VBG
the/DT
proteins/NNS
that/WDT
showed/VBD
an/DT
E-value/JJ
10â100/CD
./.
====================
Set3/NN
proteome/JJ
contains/VBZ
the/DT
proteins/NNS
of/IN
F./NNP
nucleatum/NN
that/DT
could/MD
be/VB
considered/VBN
as/IN
novel/JJ
drug/NN
targets/NNS
because/IN
they/PRP
are/VBP
not/RB
present/JJ
in/IN
the/DT
host/NN
and/CC
are/VBP
involved/VBN
in/IN
essential/JJ
metabolic/JJ
functions/NNS
in/IN
the/DT
bacterium/NN
./.
====================
Metabolic/JJ
pathway/NN
analysis/NN
====================
The/DT
human/JJ
non-homologous/JJ
essential/JJ
proteins/NNS
of/IN
F./NNP
nucleatum/NN
obtained/VBN
through/IN
BLASTP/NN
were/VBD
then/RB
subjected/VBD
to/TO
metabolic/JJ
pathway/NN
analysis/NN
,/,
which/WDT
was/VBD
done/VBN
by/IN
Kyoto/JJ
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
Automatic/JJ
Annotation/NN
Server/NN
(/(
KAAS/NN
;/:
http/RB
:/:
//www.genome.jp/tools/kaas//JJ
)/)
[/(
23/CD
]/)
at/IN
KEGG/NN
[/(
24/CD
]/)
./.
====================
The/DT
server/NN
provides/VBZ
functional/JJ
annotation/NN
of/IN
genes/NNS
by/IN
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
(/(
BLAST/NN
)/)
comparisons/NNS
against/IN
the/DT
manually/RB
curated/VBN
KEGG/NN
GENES/NN
database/NN
./.
====================
The/DT
result/NN
contains/VBZ
KEGG/NN
Orthology/NN
(/(
KO/NN
)/)
assignments/NNS
and/CC
automatically/RB
generated/VBN
KEGG/NN
pathways/NNS
./.
====================
Unique/JJ
pathway/NN
identification/NN
====================
After/IN
this/DT
,/,
unique/JJ
metabolic/JJ
pathways/NNS
of/IN
Fusobacterium/NN
nucleatum/NN
subsp/NN
./.
====================
nucleatum/NN
ATCC25586/NN
were/VBD
identified/VBN
through/IN
the/DT
comparison/NN
of/IN
metabolic/JJ
pathways/NNS
of/IN
both/DT
Fusobacterium/NN
nucleatum/NN
subsp/NN
./.
====================
nucleatum/NN
ATCC25586/NN
and/CC
Homo/NN
sapiens/NNS
by/IN
using/VBG
KEGG/NN
Genome/NN
Database/NN
[/(
25/CD
]/)
./.
====================
Among/IN
unique/JJ
metabolic/JJ
pathways/NNS
of/IN
only/RB
those/DT
proteins/NNS
were/VBD
identified/VBN
which/WDT
were/VBD
human/JJ
non-homologue/NN
essential/JJ
proteins/NNS
./.
====================
Sub-cellular/JJ
localization/NN
of/IN
unique/JJ
essential/JJ
metabolic/JJ
proteins/NNS
====================
The/DT
program/NN
PSORTb/NN
V.3.0/CD
(/(
http/NN
:/:
//www.psort.org/psortb/index.html/NN
)/)
,/,
CELLO/NN
(/(
http/NN
:/:
//cello.life.nctu.edu.tw//JJ
)/)
,/,
and/CC
SOSUI/NN
(/(
http/NN
:/:
//bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html/NN
)/)
server/RB
was/VBD
used/VBN
to/TO
characterize/VB
whether/IN
the/DT
proteins/NNS
are/VBP
soluble/JJ
or/CC
trans-membrane/JJ
in/IN
nature/NN
./.
====================
This/DT
computational/JJ
tool/NN
illustrates/VBZ
where/WRB
the/DT
protein/NN
resides/VBZ
in/IN
the/DT
cell/NN
./.
====================
So/RB
if/IN
the/DT
protein/NN
is/VBZ
associated/VBN
with/IN
the/DT
cell/NN
membrane/NN
,/,
there/EX
is/VBZ
more/RBR
possibility/NN
that/IN
it/PRP
can/MD
be/VB
highlighted/JJ
as/IN
a/DT
potential/JJ
therapeutic/JJ
target/NN
[/(
2627/CD
]/)
./.
====================
Homology/NN
modelling/VBG
ofunique/JJ
essential/JJ
metabolic/JJ
proteins/NNS
====================
To/TO
predict/VB
the/DT
3D/NN
structure/NN
of/IN
unique/JJ
essential/JJ
metabolic/JJ
proteins/NNS
,/,
homology/NN
modelling/VBG
was/VBD
done/VBN
by/IN
the/DT
server/NN
Protein/NN
Homology/Analogy/NN
Recognition/NN
Engine/NN
(/(
Phyre2/NN
)/)
./.
====================
The/DT
retrieved/JJ
amino/NN
acid/NN
sequence/NN
in/IN
FASTA/NN
format/IN
was/VBD
used/VBN
as/IN
input/NN
data/NNS
in/IN
Phyre2/NN
(/(
http/NN
:/:
//www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi/NNP
?/.
id=index/NN
)/)
./.
====================
In/IN
this/DT
respect/NN
,/,
the/DT
intensive/JJ
mode/NN
of/IN
protein/NN
modeling/VBG
was/VBD
selected/VBN
in/IN
order/NN
to/TO
get/VB
an/DT
accurate/JJ
model/NN
./.
====================
Model/NN
refinement/JJ
====================
Homology/NN
based/VBN
modeling/VBG
often/RB
contain/VBP
significant/JJ
local/JJ
distortions/NNS
,/,
including/VBG
steric/JJ
clashes/NNS
,/,
unphysical/JJ
phi/psi/NN
angles/NNS
and/CC
irregular/JJ
H-hydrogen/NN
bonding/VBG
networks/NNS
,/,
which/WDT
render/VBP
the/DT
structure/NN
models/NNS
less/RBR
useful/JJ
for/IN
high-resolution/JJ
functional/JJ
analysis/NN
./.
====================
Refinement/JJ
of/IN
structures/NNS
could/MD
be/VB
a/DT
solution/NN
of/IN
this/DT
problem/NN
[/(
28/CD
]/)
./.
====================
To/TO
refine/VB
the/DT
predicted/VBN
model/NN
Mod-Refiner/NN
(/(
http/NN
:/:
//zhanglab.ccmb.med.umich.edu/ModRefiner//JJ
)/)
;/:
an/DT
algorithm/NN
for/IN
atomic-level/JJ
,/,
high-resolution/JJ
protein/NN
structure/NN
refinement/JJ
is/VBZ
used/VBN
./.
====================
Verification/NN
and/CC
validation/NN
of/IN
the/DT
predicted/VBN
3D/NN
model/NN
====================
To/TO
check/VB
the/DT
accuracy/NN
of/IN
the/DT
predicted/VBN
3D/NN
structures/NNS
,/,
Protein/NN
Data/NNS
Bank/NN
Summary/JJ
(/(
PDBsum/NN
;/:
http/RB
:/:
//www.ebi.ac.uk/thorntonsrv/databases/pdbsum/Generate.html/NN
)/)
was/VBD
used/VBN
[/(
29/CD
]/)
./.
====================
The/DT
PDBsum/NN
generated/VBN
result/NN
was/VBD
further/RBR
subjected/VBN
to/TO
documentation/NN
analysis/NN
by/IN
PROgram/NN
to/TO
CHECK/NN
the/DT
stereochemical/JJ
quality/NN
of/IN
protein/NN
structures/NNS
(/(
PROCHECK/NN
)/)
[/(
30/CD
]/)
./.
====================
ERRAT/NN
algorithm/NN
(/(
http/NN
:/:
//nihserver.mbi.ucla.edu/ERRAT//JJ
)/)
helps/VBZ
in/IN
the/DT
assessment/NN
of/IN
the/DT
protein/NN
structure/NN
./.
====================
Verify/RB
3D/NN
(/(
http/NN
:/:
//nihserver.mbi.ucla.edu/Verify_3D/JJ
)/)
Structure/NN
Evaluation/NN
Server/NN
was/VBD
used/VBN
for/IN
3D/NN
profiling/VBG
of/IN
the/DT
residue/NN
./.
====================
Qualitative/JJ
Model/NN
Energy/NN
Analysis/NN
(/(
QMEAN/NN
;/:
http/RB
:/:
//swissmodel.expasy.org/qmean/cgi/index.cgi/NNP
)/)
was/VBD
also/RB
done/RB
which/WDT
is/VBZ
a/DT
composite/JJ
scoring/VBG
function/NN
that/IN
derives/VBZ
both/CC
global/JJ
and/CC
local/JJ
error/NN
estimates/NNS
on/IN
the/DT
basis/NN
of/IN
one/CD
single/JJ
model/NN
./.
====================
Global/JJ
error/NN
is/VBZ
estimated/VBN
for/IN
entire/JJ
structure/NN
and/CC
local/JJ
one/CD
for/IN
per/FW
residue/NN
error/NN
./.
====================
Prediction/NN
of/IN
ligand/NN
binding/NN
sites/NNS
and/CC
corresponding/JJ
ligands/NNS
====================
Once/RB
the/DT
final/JJ
model/NN
of/IN
our/PRP$
best/JJS
considered/VBN
predicted/VBN
proteins/NNS
was/VBD
built/RB
,/,
the/DT
possible/JJ
ligand/NN
binding/NN
sites/NNS
and/CC
their/PRP$
corresponding/JJ
ligands/NNS
were/VBD
revealed/VBN
using/VBG
COACH/NN
(/(
http/NN
:/:
//zhanglab.ccmb.med.umich.edu/COACH//JJ
)/)
,/,
a/DT
meta-server/JJ
approach/NN
which/WDT
uses/VBZ
BioLip/NNP
database/NN
for/IN
predicting/VBG
protein-ligand/CC
binding/VBG
site/NN
[/(
31/CD
]/)
./.
====================
Verification/NN
of/IN
the/DT
pharmaco-chemical/JJ
properties/NNS
of/IN
the/DT
best/JJS
predicted/VBN
ligands/NNS
====================
The/DT
pharmaco-chemical/JJ
properties/NNS
of/IN
the/DT
best/JJS
predicted/VBN
ligands/NNS
were/VBD
retrieved/VBN
from/IN
the/DT
DrugBank/NN
Database/NN
(/(
http/NN
:/:
//www.drugbank.ca/drugs//JJ
)/)
to/TO
demonstrate/VB
them/PRP
as/IN
potential/JJ
inhibitors/NNS
of/IN
the/DT
best/JJS
considered/VBN
target/NN
proteins/NNS
./.
====================
Among/IN
a/DT
total/JJ
of/IN
4,630/CD
proteins/NNS
of/IN
Fusobacterium/NN
nucleatum/NN
strain/NN
ATCC/NN
25586/CD
,/,
2,639/CD
proteins/NNS
were/VBD
nullified/VBN
./.
====================
In/IN
effect/NN
,/,
we/PRP
found/VBD
1,991/CD
proteins/NNS
as/IN
non-paralogous/JJ
./.
====================
BLASTP/NN
screening/NN
of/IN
these/DT
proteins/NNS
against/IN
the/DT
Homo/NN
sapiens/NNS
genome/NN
results/VBZ
in/IN
1,499/CD
proteins/NNS
which/WDT
were/VBD
non-homologous/JJ
to/TO
human/JJ
proteome/NN
./.
====================
Furthermore/RB
,/,
the/DT
1499/CD
host/NN
non-homologous/JJ
proteins/NNS
were/VBD
then/RB
screened/VBN
through/IN
DEG/NN
with/IN
an/DT
E-value/JJ
cutoff/JJ
score/RB
of/IN
10â100/CD
revealing/VBG
32/CD
essential/JJ
proteins/NNS
./.
====================
The/DT
DEG/NN
houses/NNS
the/DT
records/NNS
of/IN
presently/RB
available/JJ
essential/JJ
genes/NNS
of/IN
a/DT
number/NN
of/IN
organisms/NNS
./.
====================
With/IN
a/DT
view/NN
to/TO
identify/VB
the/DT
metabolic/JJ
function/NN
of/IN
32/CD
essential/JJ
proteins/NNS
,/,
metabolic/JJ
pathway/NN
was/VBD
analyzed/VBN
by/IN
KAAS/NN
server/RB
at/IN
KEGG/NN
identifying/VBG
a/DT
set/NN
of/IN
30/CD
proteins/NNS
as/IN
putative/JJ
drug/NN
targets/NNS
./.
====================
After/IN
that/DT
,/,
comparative/JJ
metabolic/JJ
pathway/NN
analysis/NN
of/IN
human/JJ
host/NN
and/CC
F./NNP
nucleatum/NN
was/VBD
performed/VBN
at/IN
KEGG/NN
Genome/NN
Database/NN
[/(
3233/CD
]/)
./.
====================
This/DT
comparison/NN
reveals/VBZ
12/CD
unique/JJ
pathways/NNS
which/WDT
are/VBP
present/JJ
exclusively/RB
in/IN
F./NNP
nucleatum/NN
and/CC
among/IN
those/DT
12/CD
pathways/NNS
3/CD
non-human/JJ
homologous/JJ
essential/JJ
proteins/NNS
were/VBD
found/VBN
to/TO
be/VB
present/JJ
on/IN
two/CD
different/JJ
unique/JJ
pathways/NNS
./.
====================
The/DT
results/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
Two/CD
out/RB
of/IN
three/CD
metabolic/JJ
proteins/NNS
are/VBP
involved/VBN
in/IN
phosphotransferase/NN
system/NN
(/(
PTS/NNS
)/)
and/CC
one/CD
protein/NN
is/VBZ
known/VBN
to/TO
incorporate/VB
in/IN
peptidoglycan/NN
biosynthesis/NN
./.
====================
Psortb/NN
and/CC
CELLO/NN
,/,
the/DT
two/CD
bacterial/JJ
protein/NN
subcellular/JJ
localization/NN
prediction/NN
tools/NNS
,/,
demonstrated/VBD
that/IN
these/DT
three/CD
proteins/NNS
locate/VBP
in/IN
the/DT
cytoplasmic/JJ
membrane/NN
and/CC
thereby/RB
implying/VBG
these/DT
proteins/NNS
to/TO
be/VB
promising/JJ
drug/NN
target/NN
site/NN
./.
====================
The/DT
server/NN
SOSUI/NN
discriminates/VBZ
whether/IN
the/DT
proteins/NNS
are/VBP
soluble/JJ
or/CC
membranous/JJ
./.
====================
Two/CD
proteins/NNS
were/VBD
soluble/JJ
namely/RB
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
,/,
PTS/NN
system/NN
fructose-specific/JJ
IIABC/NN
component/NN
,/,
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
was/VBD
trans-membrane/JJ
protein/NN
(/(
Table/JJ
2/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
./.
====================
3D/RB
structures/NNS
of/IN
the/DT
three/CD
unique/JJ
and/CC
essential/JJ
metabolic/JJ
proteins/NNS
were/VBD
obtained/VBN
by/IN
homology/NN
modeling/VBG
using/VBG
Phyre2/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
ModRefiner/NN
derived/VBN
refined/VBD
model/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
were/VBD
analyzed/VBN
./.
====================
In/IN
case/NN
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
in/IN
initial/JJ
model/NN
the/DT
percent/JJ
of/IN
residues/NNS
in/IN
favored/JJ
region/NN
were/VBD
91.0/CD
%/NN
whereas/IN
92.1/CD
%/NN
in/IN
the/DT
final/JJ
model/NN
./.
====================
Though/IN
in/IN
case/NN
of/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
amino/NN
acids/NNS
residue/NN
in/IN
favored/JJ
region/NN
were/VBD
same/JJ
in/IN
both/DT
the/DT
initial/JJ
and/CC
final/JJ
model/NN
but/CC
has/VBZ
a/DT
change/NN
in/IN
disallowed/JJ
region/NN
,/,
initially/RB
disallowed/VBN
region/NN
had/VBD
0.5/CD
%/NN
residues/NNS
and/CC
after/IN
refinement/JJ
it/PRP
narrowed/VBD
down/RB
to/TO
0.0/CD
%/NN
./.
====================
After/IN
that/DT
,/,
PROCHECK/NN
was/VBD
used/VBN
to/TO
measure/VB
the/DT
stereo-chemical/JJ
quality/NN
of/IN
protein/NN
models/NNS
at/IN
a/DT
resolution/NN
of/IN
1.8/CD
./.
====================
PROCHECK/NN
renders/VBZ
information/NN
about/IN
the/DT
protein/NN
chains/NNS
and/CC
stereo-chemical/JJ
properties/NNS
such/JJ
as/IN
Ramachandran/NN
plot/NN
quality/NN
,/,
peptide/NN
bond/NN
planarity/NN
,/,
bad/NN
non-bonded/JJ
interactions/NNS
,/,
main/JJ
chain/NN
hydrogen/NN
bond/NN
energy/NN
,/,
C/NN
alpha/NN
chirality/NN
and/CC
overall/JJ
G/NN
factor/NN
[/(
34/CD
]/)
./.
====================
Ramachandran/NN
plot/NN
regarding/VBG
this/DT
analysis/NN
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
5/CD
./.
====================
Moreover/RB
,/,
verification/NN
of/IN
the/DT
refinement/JJ
was/VBD
performed/VBN
by/IN
Errat/NN
,/,
QMEAN/NN
server/RB
,/,
and/CC
Verify/RB
3D/NN
./.
====================
Errat/NN
is/VBZ
particularly/RB
appropriate/JJ
for/IN
assessing/VBG
the/DT
progress/NN
of/IN
crystallographic/JJ
model/NN
building/VBG
and/CC
refinement/JJ
./.
====================
Errat/NN
showed/VBD
the/DT
comparative/JJ
error/NN
value/NN
of/IN
the/DT
structured/JJ
model/NN
./.
====================
The/DT
overall/JJ
quality/NN
of/IN
model/NN
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
in/IN
ERRAT/NN
analysis/NN
was/VBD
81.961/CD
while/IN
in/IN
case/NN
of/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
is/VBZ
79.952/CD
./.
====================
The/DT
respective/JJ
values/NNS
of/IN
torsion/NN
angle/JJ
energy/NN
,/,
C_Î²/NNP
interaction/NN
energy/NN
,/,
solvation/JJ
energy/NN
,/,
secondary/JJ
structure/NN
,/,
and/CC
solvent/JJ
accessibility/NN
are/VBP
â1.46/CD
,/,
0.38/CD
,/,
0.74/CD
,/,
1.83/CD
,/,
and/CC
0.08/CD
in/IN
case/NN
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
where/WRB
â0.12/NN
,/,
0.75/CD
,/,
â1.91/CD
,/,
0.50/CD
,/,
â0.00/CD
in/IN
case/NN
of/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/JJ
./.
====================
The/DT
QMEAN/NN
for/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
and/CC
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
is/VBZ
0.751/CD
and/CC
0.714/CD
,/,
respectively/RB
./.
====================
Z/NN
score/NN
result/NN
is/VBZ
also/RB
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
COACH/NN
generates/VBZ
protein-ligand/CC
binding/VBG
site/NN
on/IN
the/DT
basis/NN
of/IN
two/CD
developed/VBD
method/NN
(/(
TM-SITE/NN
,/,
based/VBN
on/IN
binding-specific/JJ
substructure/NN
comparison/NN
and/CC
S-SITE/NN
,/,
based/VBN
on/IN
sequence/NN
profile/NN
alignment/NN
)/)
along/IN
with/IN
considering/VBG
COFACTOR/NN
,/,
FINDSITE/NN
,/,
and/CC
CONCAVITY/NN
results/NNS
./.
====================
CONCAVITY/NN
results/VBZ
showed/VBD
that/IN
a/DT
total/JJ
number/NN
of/IN
27/CD
residues/NNS
(/(
â196/CD
,/,
199/CD
,/,
281/CD
,/,
301/CD
,/,
303/CD
,/,
305/CD
,/,
306/CD
,/,
339/CD
,/,
342/CD
,/,
343/CD
,/,
344/CD
,/,
345/CD
,/,
347/CD
,/,
361/CD
,/,
365/CD
,/,
436/CD
,/,
438/CD
,/,
459/CD
,/,
461/CD
,/,
462/CD
,/,
466/CD
,/,
472/CD
,/,
509/CD
,/,
510/CD
,/,
531/CD
,/,
532/CD
,/,
and/CC
533/CD
)/)
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
are/VBP
associated/VBN
with/IN
creating/VBG
ligand/NN
binding/NN
pocket/NN
./.
====================
A/DT
similar/JJ
pattern/NN
of/IN
concavity/NN
result/RB
was/VBD
also/RB
found/VBN
for/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/JJ
in/IN
which/WDT
a/DT
total/JJ
number/NN
of/IN
forty/RB
amino/NN
acid/NN
residues/NNS
were/VBD
involved/VBN
in/IN
comprising/VBG
the/DT
ligand/NN
binding/VBG
pocket/RB
of/IN
the/DT
proteins/NNS
(/(
23/CD
,/,
24/CD
,/,
27/CD
,/,
50/CD
,/,
91/CD
,/,
94/CD
,/,
95/CD
,/,
115/CD
,/,
116/CD
,/,
118/CD
,/,
120/CD
,/,
123/CD
,/,
124/CD
,/,
125/CD
,/,
128/CD
,/,
164/CD
,/,
165/CD
,/,
166/CD
,/,
167/CD
,/,
170/CD
,/,
191/CD
,/,
193/CD
,/,
234/CD
,/,
235/CD
,/,
236/CD
,/,
240/CD
,/,
261/CD
,/,
300/CD
,/,
301/CD
,/,
302/CD
,/,
306/CD
,/,
307/RB
,/,
308/CD
,/,
330/CD
,/,
331/CD
,/,
373/CD
,/,
374/CD
,/,
400/CD
,/,
401/CD
,/,
and/CC
402/CD
)/)
./.
====================
Furthermore/RB
,/,
S-SITE/NN
result/NN
represents/VBZ
the/DT
possible/JJ
ligands/NNS
that/DT
can/MD
bind/VB
with/IN
phosphoenolpyruvate-protein/NN
phosphotransferas/NNS
as/IN
well/RB
as/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
and/CC
ranked/VBD
them/PRP
according/VBG
to/TO
confidence/VB
score/RB
(/(
C-score/NNP
)/)
,/,
C-score/RB
ranges/VBZ
from/IN
0/CD
to/TO
1/CD
where/WRB
a/DT
higher/JJR
score/RB
implies/VBZ
a/DT
more/RBR
reliable/JJ
prediction/NN
./.
====================
Among/IN
the/DT
predicted/VBN
ligands/NNS
for/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
,/,
PPR/NN
or/CC
3-phosphonopyruvate/JJ
was/VBD
exhibited/VBD
as/IN
the/DT
top/NN
ranked/VBD
ligand/NN
having/VBG
a/DT
confidence/NN
score/RB
(/(
C-score/NNP
)/)
of/IN
0.45/CD
and/CC
interacting/VBG
with/IN
total/JJ
eleven/JJ
residues/NNS
(/(
301/CD
,/,
303/CD
,/,
339/CD
,/,
436/CD
,/,
438/CD
,/,
459/CD
,/,
460/CD
,/,
461/CD
,/,
462/CD
,/,
509/CD
,/,
and/CC
510/CD
)/)
those/DT
are/VBP
also/RB
resides/VBZ
within/IN
predicted/VBN
ligand/NN
binding/NN
pocket/NN
of/IN
the/DT
protein/NN
./.
====================
The/DT
best/JJS
predicted/VBN
ligand/NN
for/IN
N-acetylglucosamine/NN
1-carboxyvinyl-transferase/JJ
was/VBD
SKP/NN
or/CC
5-/CD
(/(
1-carboxy-1-phosphonooxy-ethoxyl/JJ
)/)
-shikimate-3-phosphate/JJ
,/,
representing/VBG
C-score/RB
0.41/CD
and/CC
interacting/VBG
with/IN
total/JJ
number/NN
of/IN
sixteen/CD
residues/NNS
(/(
23/CD
,/,
24/CD
,/,
28/CD
,/,
94/CD
,/,
95/CD
,/,
98/CD
,/,
123/CD
,/,
165/CD
,/,
166/CD
,/,
167/CD
,/,
308/CD
,/,
330/CD
,/,
334/CD
,/,
373/CD
,/,
374/CD
,/,
and/CC
400/CD
)/)
that/IN
are/VBP
also/RB
common/JJ
in/IN
the/DT
ligand/NN
binding/NN
pocket/NN
of/IN
the/DT
protein/NN
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
To/TO
nullify/VB
the/DT
2,643/CD
proteins/NNS
from/IN
total/JJ
4,630/CD
redundant/JJ
proteins/NNS
of/IN
F./NN
nucleatum/NN
stain/NN
ATCC/NN
25586/CD
the/DT
CD-HIT/NN
program/NN
used/VBN
at/IN
60/CD
%/NN
identity/NN
[/(
3536/CD
]/)
./.
====================
After/IN
BLASTP/NN
analysis/NN
,/,
human/JJ
non-homologous/JJ
proteins/NNS
were/VBD
selected/VBN
to/TO
avoid/VB
unwanted/JJ
cross-reactions/NNS
and/CC
cytotoxicity/NN
./.
====================
BLASTP/NN
against/IN
DEG/NN
identified/VBN
the/DT
essential/JJ
genes/NNS
./.
====================
The/DT
genes/NNS
that/WDT
are/VBP
vital/JJ
to/TO
maintain/VB
cellular/JJ
life/NN
are/VBP
referred/VBN
to/TO
as/IN
essential/JJ
genes/NNS
./.
====================
Essential/JJ
gene/NN
products/NNS
of/IN
pathogen/NN
can/MD
become/VB
promising/VBG
novel/JJ
drug/NN
targets/NNS
owing/VBG
to/TO
the/DT
reason/NN
that/DT
most/JJS
antibiotics/NNS
attack/NN
cellular/JJ
processes/NNS
in/IN
bacteria/NNS
[/(
3237/CD
]/)
./.
====================
Essential/JJ
genes/NNS
which/WDT
are/VBP
exclusive/JJ
to/TO
an/DT
organism/NN
can/MD
be/VB
regarded/VBN
as/IN
species-specific/JJ
therapeutic/JJ
targets/NNS
[/(
33/CD
]/)
./.
====================
Sub-cellular/JJ
localization/NN
of/IN
proteins/NNS
has/VBZ
an/DT
important/JJ
role/NN
in/IN
drug/NN
targets/NNS
prediction/NN
arena/NNS
./.
====================
Proteins/NNS
situated/JJ
in/IN
cytoplasmic/JJ
membrane/NN
are/VBP
considered/VBN
more/RBR
valuable/JJ
for/IN
target/NN
site/NN
./.
====================
3D/RB
structure/NN
of/IN
protein/NN
molecules/NNS
exposes/VBZ
the/DT
molecular/JJ
basis/NN
of/IN
protein/NN
function/NN
and/CC
thus/RB
allows/VBZ
an/DT
efficient/JJ
design/NN
of/IN
experiments/NNS
,/,
for/IN
example/NN
,/,
site-directed/JJ
mutagenesis/NN
,/,
disease-related/JJ
mutation/NN
analysis/NN
,/,
or/CC
the/DT
structure/NN
based/VBN
design/NN
of/IN
specific/JJ
inhibitors/NNS
[/(
38/CD
]/)
./.
====================
That/DT
is/VBZ
why/WRB
,/,
the/DT
determination/NN
of/IN
the/DT
3D/NN
structure/NN
of/IN
a/DT
protein/NN
molecule/NN
is/VBZ
central/JJ
to/TO
its/PRP$
understanding/NN
and/CC
manipulation/NN
of/IN
biochemical/JJ
and/CC
cellular/JJ
functions/NNS
[/(
39/CD
]/)
./.
====================
In/IN
case/NN
of/IN
each/DT
protein/NN
,/,
greater/JJR
than/IN
90/CD
%/NN
confidence/NN
match/VBP
was/VBD
obtained/VBN
except/IN
PTS/NN
system/NN
fructose-specific/JJ
IIABC/NN
component/NN
protein/NN
./.
====================
A/DT
high/JJ
confidence/NN
match/VBP
indicates/VBZ
that/IN
,/,
overall/JJ
fold/JJ
of/IN
the/DT
models/NNS
were/VBD
almost/RB
accurate/JJ
and/CC
the/DT
central/JJ
core/NN
of/IN
the/DT
model/NN
was/VBD
correct/JJ
as/IN
well/RB
[/(
34/CD
]/)
./.
====================
Ramachandran/NN
plot/NN
statistics/NNS
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
showed/VBD
that/IN
most/JJS
of/IN
the/DT
amino/NN
acid/NN
residues/NNS
(/(
above/JJ
90/CD
%/NN
of/IN
amino/NN
acid/NN
residues/NNS
)/)
were/VBD
found/VBN
in/IN
most/JJS
favoured/VBD
regions/NNS
indicating/VBG
that/IN
the/DT
protein/NN
models/NNS
were/VBD
of/IN
very/RB
good/JJ
quality/NN
./.
====================
The/DT
program/NN
functions/NNS
based/VBN
on/IN
the/DT
analysis/NN
of/IN
statistics/NNS
of/IN
non-bonded/JJ
interactions/NNS
between/IN
different/JJ
atom/IN
types/NNS
[/(
40/CD
]/)
./.
====================
Verify/RB
3D/NN
graph/NN
and/CC
a/DT
value/NN
of/IN
0.85/CD
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
in/IN
contrast/NN
to/TO
the/DT
value/NN
0.72/CD
for/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
indicates/VBZ
that/IN
environmental/JJ
profile/NN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
is/VBZ
fairly/RB
good/JJ
[/(
4142/CD
]/)
./.
====================
The/DT
QMEAN/NN
assesses/NNS
the/DT
global/JJ
quality/NN
of/IN
the/DT
models/NNS
based/VBN
on/IN
a/DT
linear/JJ
combination/NN
of/IN
six/CD
structural/JJ
descriptions/NNS
./.
====================
The/DT
local/JJ
geometry/NN
model/NN
is/VBZ
analyzed/VBN
by/IN
calculating/VBG
torsion/NN
angel/NN
potential/JJ
over/IN
three/CD
consecutive/JJ
amino/NN
acids/NNS
./.
====================
The/DT
long/JJ
range/NN
interactions/NNS
are/VBP
assessed/VBN
by/IN
estimating/VBG
secondary/JJ
structure/NN
specific/JJ
distance/NN
dependent/JJ
pairwise/JJ
residue/NN
level/NN
potential/JJ
./.
====================
A/DT
solvation/JJ
potential/JJ
reveals/VBZ
the/DT
burial/JJ
state/NN
of/IN
the/DT
residues/NNS
./.
====================
Simple/JJ
sequence/NN
editor/NN
and/CC
auto/JJ
cross/JJ
covariance/NN
conformity/NN
indicates/VBZ
that/IN
the/DT
assessment/NN
between/IN
the/DT
predicted/VBN
and/CC
calculated/VBN
secondary/JJ
structure/NN
and/CC
solvent/JJ
accessibility/NN
is/VBZ
of/IN
good/JJ
quality/NN
[/(
434445/CD
]/)
./.
====================
Specifying/JJ
exact/JJ
ligand-binding/JJ
site/NN
on/IN
protein/NN
is/VBZ
a/DT
crucial/JJ
step/NN
in/IN
rational/JJ
designing/VBG
of/IN
novel/JJ
therapeutic/JJ
molecules/NNS
to/TO
modulate/VB
the/DT
protein/NN
functions/VBZ
[/(
46/CD
]/)
./.
====================
TM-SITE/DT
and/CC
S-SITE/NN
,/,
along/IN
with/IN
considering/VBG
COFACTOR/NN
,/,
FINDSITE/NN
,/,
and/CC
CONCAVITY/NN
results/NNS
which/WDT
increases/VBZ
Matthews/NNS
correlation/NN
coefficient/JJ
by/IN
15/CD
%/NN
over/IN
the/DT
best/JJS
individual/JJ
predictions/NNS
and/CC
these/DT
predictions/NNS
are/VBP
considered/VBN
reliable/JJ
and/CC
accurate/JJ
in/IN
recent/JJ
times/NNS
[/(
47/CD
]/)
./.
====================
Moreover/RB
,/,
pharmaco-chemical/JJ
properties/NNS
of/IN
the/DT
PPR/NN
and/CC
SKP/NN
that/DT
were/VBD
retrieved/VBN
from/IN
the/DT
DrugBank/NN
Database/NN
indicate/VBP
that/IN
these/DT
compounds/NNS
are/VBP
non-carcinogenic/JJ
,/,
non-toxic/JJ
and/CC
moderately/RB
absorbable/JJ
by/IN
human/JJ
intestine/NN
(/(
absorption/NN
probability/NN
,/,
0.7197/CD
and/CC
0.5233/CD
,/,
respectively/RB
)/)
[/(
48/CD
]/)
./.
====================
Hence/RB
,/,
the/DT
activity/NN
of/IN
the/DT
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
can/MD
be/VB
inhibited/VBN
by/IN
the/DT
PPR/NN
,/,
derivatives/NNS
of/IN
PPR/NN
or/CC
PPR/NN
related/JJ
compounds/NNS
./.
====================
Likewise/RB
,/,
the/DT
activity/NN
of/IN
the/DT
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
probably/RB
can/MD
be/VB
hindered/VBN
by/IN
SKP/NN
,/,
derivatives/NNS
of/IN
SKP/NN
or/CC
SKP/NN
related/JJ
molecules/NNS
./.
====================
Since/IN
,/,
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
and/CC
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
were/VBD
identified/VBN
as/IN
the/DT
essential/JJ
proteins/NNS
for/IN
the/DT
bacterial/JJ
survival/NN
,/,
blocking/VBG
the/DT
function/NN
of/IN
these/DT
two/CD
enzymes/NNS
can/MD
be/VB
a/DT
novel/JJ
way/NN
to/TO
treat/VB
F./NNP
nucleatumâassociated/JJ
diseases/NNS
./.
====================
However/RB
,/,
further/RBR
research/NN
should/MD
be/VB
conducted/VBN
both/CC
in/FW
vivo/FW
and/CC
in/IN
vitro/FW
to/TO
ascertain/VB
this/DT
result/NN
./.
====================
Understanding/VBG
the/DT
docking/NN
studies/NNS
with/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
,/,
PTS/NN
system/NN
fructose-specific/JJ
IIABC/NN
component/NN
,/,
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyl/JJ
transferase/NN
protein/NN
as/IN
a/DT
receptor/NN
and/CC
protoporphyrin/NN
IX/CD
as/IN
a/DT
ligand/NN
./.
====================
Analysis/NN
of/IN
the/DT
lowest/JJS
docked/VBD
energy/NN
value/NN
,/,
the/DT
involvement/NN
of/IN
H-bonds/NNS
,/,
calculated/VBN
root/NN
mean/NN
square/VBP
deviation/NN
value/NN
,/,
and/CC
interacting/VBG
residues/NNS
was/VBD
considered/VBN
[/(
49/CD
]/)
./.
====================
The/DT
interactions/NNS
between/IN
the/DT
amino/NN
acid/NN
residues/NNS
in/IN
active/JJ
sites/NNS
and/CC
the/DT
ligand/NN
molecules/NNS
derived/VBN
in/IN
this/DT
study/NN
would/MD
be/VB
valuable/JJ
to/TO
understand/VB
the/DT
potential/JJ
mechanism/NN
of/IN
residues/NNS
and/CC
the/DT
drug/NN
binding/NN
./.
====================
It/PRP
is/VBZ
evident/JJ
that/IN
that/WDT
protoporphyrin/NN
IX/CD
is/VBZ
involved/VBN
in/IN
similar/JJ
hydrogen/NN
bond/NN
interactions/NNS
with/IN
proteins/NNS
and/CC
thus/RB
the/DT
results/NNS
found/VBD
in/IN
our/PRP$
study/NN
are/VBP
significant/JJ
./.
====================
However/RB
,/,
to/TO
consider/VB
these/DT
proteins/NNS
as/IN
valid/JJ
target/NN
for/IN
drug/NN
designing/VBG
,/,
the/DT
future/JJ
researchers/NNS
also/RB
need/VBD
to/TO
think/VB
about/RB
the/DT
possibility/NN
that/IN
these/DT
same/JJ
functional/JJ
proteins/NNS
may/MD
exist/VB
in/IN
some/DT
other/JJ
beneficial/JJ
bacteria/NNS
from/IN
human/JJ
microbiota/NNS
./.
====================
In/IN
conclusion/NN
,/,
in/IN
this/DT
era/NN
of/IN
genomic/JJ
science/NN
,/,
subtractive/JJ
genomic/JJ
approach/NN
to/TO
drug/NN
designing/VBG
has/VBZ
been/VBN
greatly/RB
facilitated/VBN
by/IN
the/DT
plethora/NN
of/IN
bacterial/JJ
genomic/JJ
information/NN
./.
====================
The/DT
demand/CC
for/IN
new/JJ
classes/NNS
of/IN
antibacterial/JJ
drug/NN
is/VBZ
increasingly/RB
growing/VBG
as/IN
drug/NN
resistance/NN
challenges/NNS
the/DT
effectiveness/NN
of/IN
existing/VBG
therapies/NNS
./.
====================
Hence/RB
,/,
there/EX
are/VBP
obvious/JJ
benefits/VBZ
for/IN
the/DT
identification/NN
and/CC
evaluation/NN
of/IN
new/JJ
therapeutic/JJ
targets/NNS
and/CC
which/WDT
is/VBZ
why/RB
this/DT
study/NN
has/VBZ
scrutinized/VBN
the/DT
proteome/JJ
of/IN
oral/JJ
pathogen/NN
F./NNP
nucleatum/NN
adopting/VBG
the/DT
subtractive/JJ
genomic/JJ
approach/NN
and/CC
identified/VBD
two/CD
promising/VBG
novel/JJ
therapeutic/JJ
targets/NNS
along/IN
with/IN
predicting/VBG
their/PRP$
3D/NN
structures/NNS
,/,
ligand/NN
binding/NN
sites/NNS
and/CC
corresponding/VBG
ligands/NNS
as/IN
well/RB
./.
====================
These/DT
findings/NNS
have/VBP
now/RB
paved/VBN
the/DT
way/NN
for/IN
design/NN
and/CC
development/NN
of/IN
novel/JJ
inhibitors/NNS
for/IN
F./NN
nucleatum/NN
using/VBG
the/DT
structure/NN
based/VBN
drug/NN
design/NN
strategy/NN
./.
====================
Flowchart/NN
./.
====================
A/DT
schematic/JJ
representation/NN
of/IN
process/NN
analysis/NN
and/CC
interpretations/NNS
./.
====================
FASTA/NN
,/,
FAST/NN
alignment/NN
;/:
CD-HIT/NN
,/,
Cluster/NN
Database/NN
at/IN
High/JJ
Identity/NN
with/IN
Tolerance/NN
;/:
P/NN
BLAST/NN
,/,
Protein/NN
Basic/JJ
Local/JJ
Alignment/JJ
Search/NN
Tool/NN
;/:
DEG/NN
,/,
Database/NN
of/IN
Essential/JJ
Genes/NNS
./.
====================
SOSUI/NN
result/NN
of/IN
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
./.
====================
Homology/NN
modeling/VBG
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
(/(
A/NN
)/)
,/,
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
(/(
B/NN
)/)
,/,
and/CC
phosphotransferase/NN
system/NN
fructose-specific/JJ
IIABC/NN
component/NN
(/(
C/NN
)/)
./.
====================
ModRefiner/NN
derived/VBN
model/NN
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
(/(
A/NN
)/)
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
(/(
B/NN
)/)
./.
====================
Ramachandran/NN
plot/NN
of/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
(/(
A/NN
)/)
and/CC
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
(/(
B/NN
)/)
./.
====================
Ligand/NN
binding/VBG
pocket/NN
of/IN
the/DT
protein/NN
molecular/JJ
interactions/NNS
of/IN
PPR/NN
with/IN
phosphoenolpyruvate-protein/NN
phosphotransferase/NN
(/(
A/DT
)/)
and/CC
molecular/JJ
interactions/NNS
of/IN
SKP/NN
with/IN
N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
(/(
B/NN
)/)
./.
====================
Results/NNS
of/IN
subtractive/JJ
genomic/JJ
and/CC
metabolic/JJ
pathway/NN
analysis/NN
for/IN
Fusobacterium/NN
nucleatum/NN
subsp/NN
./.
====================
nucleatum/NN
ATCC/NN
25586/CD
====================
SOSUI/NN
result/NN
of/IN
UDP-N-acetylglucosamine/NN
1-carboxyvinyltransferase/NN
====================
Z-scores/NNS
of/IN
QMEAN/NN
for/IN
individual/JJ
component/NN
====================
